Rodríguez Pérez, Aurora http://orcid.org/0000-0001-6591-7109
Felip Font, Enriqueta
Chicas-Sett, Rodolfo
Montero-Luis, Ángel
de Paz Arias, Laura
González-del-Alba, Aránzazu
López-Campos, Fernando
López López, Carlos
Hernando Requejo, Ovidio
Conde-Moreno, Antonio José
Arranz Arija, José Ángel
de Castro Carpeño, Javier
Article History
Received: 29 July 2022
Accepted: 8 November 2022
First Online: 16 December 2022
Declarations
:
: EFF has received consultancy honoraria from Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Daiichi Dankyo, Eli Lilly, F. Hoffmann-La Roche, Glaxo Smith Kline, Janssen, Merck Sharp and Dome, Merck Serono, Novartis, Peptomyc, Pfizer, Sanofi and Takeda; and speaker honoraria from Amgen, Astrazeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen, Medscape, Merck Sharp and Dome, Peervoice, Pfizer, Medical Trends, Merck Serono, Sanofi, Takeda and TouchOncology; RCh-S, has received honoraria for speaking engagements from Astrazeneca, Fresenius-Kabi, Grunenthal and Adventia Pharma; and declares financial relationship with Fresenius-Kabi and Adventia Pharma. AGdA, has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen; and honoraria for speaking engagements, membership of advisory boards and continuing medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Merck, Eusa Pharma, Eisai and Astra Zeneca. JAA has received speaker honoraria from Astellas Pharma, Pfizer and Bristol-Myers Squibb, and consultancy fees from Pfizer, Astellas Pharma, Janssen-Cilag, MSD Oncology, BMS, Merck, AstraZeneca, Bayer, Eisai and Novartis. JdCC has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Hoffmann- La Roche and Takeda. All other authors declare no relevant financial or non-financial interests to disclose.
: Not applicable.